Epigenetics Market worth $3.92 billion by 2031 | MarketsandMarkets™

2026-06-26 · Source: The AI Journal · Field: Business & Management — Corporate Strategy & Leadership, Consulting & Professional Services, Biotechnology Market Analysis · Depth: Novice, medium

Summary

The epigenetics market is projected to expand significantly, growing from USD 2.22 billion in 2026 to USD 3.92 billion by 2031, demonstrating a 12.0% CAGR. This growth is driven by increasing adoption of epigenomic technologies by pharmaceutical and biotechnology companies, clinical laboratories, CROs, and academic research institutes. Key applications include drug discovery, oncology research, precision medicine, and biomarker discovery. In 2025, DNA methylation accounted for 56.2% of the market by method, while academic & research institutes held 45.9% by end-user. North America led regionally with 41.7% market share. Kits & reagents dominated the product segment, and next-generation sequencing held the largest share by technology, reflecting demand for high-throughput epigenetic profiling.

Key takeaway

For executives and investors evaluating growth opportunities in life sciences, the epigenetics market presents a compelling investment case with a projected 12.0% CAGR through 2031. Focus your strategic planning on North America, and consider companies specializing in DNA methylation analysis, next-generation sequencing, and recurring kits & reagents. This market's expansion, fueled by drug discovery and precision medicine, signals sustained demand for advanced epigenomic tools.

Key insights

The epigenetics market is poised for substantial growth, driven by diverse applications in research and medicine and advanced technological adoption.

Principles

• DNA methylation is the leading epigenetics analysis method.
• Kits & reagents are the largest product segment due to recurring use.
• Next-generation sequencing dominates epigenomic technology adoption.

In practice

• Prioritize DNA methylation-focused product development.
• Integrate NGS for high-throughput epigenetic profiling.
• Target academic and pharmaceutical research sectors.

Topics

• Epigenetics Market
• DNA Methylation
• Next-Generation Sequencing
• Biomarker Discovery
• Oncology Research
• Precision Medicine

Best for: Entrepreneur, Executive, Investor, Consultant

Related on AIssential

• Biotech Has to Change — Biotech faces immense cost and time pressures due to high failure rates in drug development.
• Dissecting epigenetic heterogeneity in single-cell DNA methylomes with a unified framework — scMethCraft accurately models single-cell DNA methylation data by addressing its unique characteristics with a hybrid neural network.
• Tissium raises €30M in equity funding, €30M in debt — Tissium's biomorphic programmable polymers offer a non-invasive tissue repair solution, securing significant funding for US expansion.
• Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million — Bridging US biopharma expertise with Europe's ecosystem creates significant life sciences investment opportunities.
• Weekly Dose of Optimism #197 — Advanced technologies are accelerating progress across architecture, medicine, defense, and manufacturing, driving significant breakthroughs.
• Cricketer Pat Cummins backs longevity startup Everlab’s $65 million Series A - Startup Daily — AI-enhanced preventative healthcare leverages biomarker diagnostics to detect early health issues and coordinate personalized care.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The AI Journal.